文献速递妇科

M-TRAP:转移性肿瘤细胞捕获装置在晚期卵巢癌患者中的安全性与性能

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
PubMed 文献 · Gynecol Oncol · 2021-03-29

本首次人体前瞻性多中心非盲单臂研究纳入23例高级别浆液性晚期卵巢癌女性,在初次或间歇性减瘤术后腹腔放置3个M-Trap装置。主要安全终点未达到(p=0.131),仅1例主要不良事件归因于装置,18例(78.3%)无装置或操作相关MAE;62%复发患者至少一个装置捕获到肿瘤细胞但浸润极少,次要性能终点显示缺乏疾病局灶化。

要点

  • M-Trap装置主要安全终点未达到预设历史对照(p=0.131)。
  • 18/23例(78.3%)无装置或操作相关主要不良事件。
  • 62%复发患者至少一个装置捕获肿瘤细胞,但浸润极少。

核心结论

  • M-Trap技术未达到主要安全目标,但按手术复杂度校正后研究认为可接受。
  • 装置在复发卵巢癌中未展现预期的肿瘤细胞捕获和疾病局灶化获益。

研究设计与样本

  • 首次人体前瞻性、多中心、非盲、单臂研究,纳入23例高级别浆液性晚期卵巢癌女性。
  • 初次或间歇性减瘤术后腹腔放置3个M-Trap装置,植入后18个月或疾病进展时经腹腔镜取出。

主要发现

  • 仅1例主要不良事件归因于装置,18例(78.3%)无装置或操作相关MAE。
  • 主要安全终点未达到(p=0.131),主要归因于M-Trap患者人群手术复杂度更高。
  • 62%复发患者至少一个装置显示肿瘤细胞捕获,浸润极少。
  • 未报告其他长期装置相关不良事件,次要性能终点显示缺乏疾病局灶化。

临床怎么用

  • 该装置尚未证明可安全有效地捕获腹膜播散肿瘤细胞或实现疾病局灶化,暂不适用于常规临床。

局限性

  • 单臂设计,主要安全终点采用历史对照。
  • 样本量小(23例),随访至植入后18个月或疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. METHODS: This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary safety endpoint was freedom from device and procedure-related major adverse events (MAEs) through 6-months post-implantation compared to an historical control. The primary performance endpoint was histopathologic evidence of tumor cells capture. RESULTS: Only one major adverse event was attributable to the device. 18 women were free of device and procedure related MAEs (78.3%). However, the primary safety endpoint was not achieved (p = 0.131), primarily attributable to the greater surgical complexity of the M-Trap patient population. 62% of recurrent patients demonstrated tumor cell capture in at least one device with a minimal tumor cell infiltration. No other long-term device-related adverse events were reported. The secondary performance endpoint demonstrated a lack of disease focalization. CONCLUSIONS: The M-Trap technology failed to meet its primary safety objective, although when adjusted for surgical complexity, the study approved it. Likewise, the devices did not demonstrate the anticipated benefits in terms of tumor cell capture and disease focalization in recurrent ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gil-Moreno A, Alonso-Alconada L, Díaz-Feijoo B, et al. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. Gynecol Oncol. 2021. PMID: 33795131. doi:10.1016/j.ygyno.2021.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。